Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IBOX updated!
WaMu: The Equity Is Striking Back
by: Troy Racki January 22, 2010
about: JPM / WAMUQ.PK
http://seekingalpha.com/article/183975-wamu-the-equity-is-striking-back?source=feed
Stocks sink again on Obama's pushback on banks
Stocks retreat for a 3rd day as investors fret over Obama's financial overhaul plan
Stephen Bernard and Tim Paradis, AP Business Writers,
Friday January 22, 2010, 4:42 pm
http://finance.yahoo.com/news/Obamas-pushback-on-banks-apf-2216140406.html?x=0&sec=topStories&pos=main&asset=&ccode=
ProLogis Closes on Euro 622 Million of Financings for European Property Funds
Date : 01/22/2010 @ 3:00AM
Source : PR Newswire
Stock : Prologis (PLD)
http://ih.advfn.com/p.php?pid=nmona&article=41213801&symbol=PLD
DENVER, Jan. 22 /PRNewswire-FirstCall/ --
ProLogis (NYSE:PLD), a leading global provider of distribution facilities, announced today that over the past four weeks it has completed four financings for its European property funds, totaling euro 622 million. The four financings have a weighted average coupon of 4.91 percent
Three, four-year financings, resulting in euro 441 million of funding, were completed for ProLogis European Properties (Euronext: PEPR). They have loan-to-value ratios of between 50 and 55 percent and are secured by assets located in Germany, Belgium, France, Italy, Spain, Poland and the United Kingdom. The largest component of these financings is a euro 300 million Pan-European, syndicated loan with six European lenders, arranged by Goldman Sachs, which was one of the largest loans of this kind done in the European real estate sector since 2008
ProLogis also completed a euro 181 million financing for ProLogis European Properties Fund II, the largest single-lender mortgage financing completed in Europe since the fall of 2008. This financing is secured by 22 assets in France and has a loan-to-value ratio of 60 percent
"With these financings, we have reduced 2010 maturities within the two funds to under euro 336 million - significant progress from the euro 1.8 billion we were faced with as of December 31, 2008. With the capital transactions in progress and available liquidity within the funds, we are comfortable with our ability to address the remaining maturities in the near future," said William E. Sullivan, ProLogis' chief financial officer. "The European financing market continues to demonstrate its diversity and resilience, as we are able to complete transactions with a wide spectrum of lenders at attractive rates."
About ProLogis
ProLogis is a leading global provider of distribution facilities, with more than 475 million square feet of industrial space (44 million square meters) in markets across North America, Europe and Asia. The company leases its industrial facilities to more than 4,500 customers, including manufacturers, retailers, transportation companies, third-party logistics providers and other enterprises with large-scale distribution needs. For additional information about the company, go to http://www.prologis.com/.
DATASOURCE: ProLogis
CONTACT: Investors, Melissa Marsden, +1-303-567-5622,
, or Media, Krista Shepard, +1-303-567-5907,
, both of ProLogis; or Financial Media, Suzanne Dawson of
Linden Alschuler & Kaplan, Inc., +1-212-329-1427, , for
ProLogis
Web Site: http://www.prologis.com/
Trade updates on NewCardio, Inc (OTC:NWCI), ...
Written by M.E.Garza
Friday, 22 January 2010 05:17
http://biomedreports.com/articles/most-popular/25814-bio-notes-newcardio-inc-otcnwci-neostem-amex-nbs-hana-biosciences-otchnab-cytrx-corporation-nasdaqcytr.html
I've received more email about NewCardio, Inc (OTC:NWCI) than any other company the last two days.
The stock went crazy after I revealed news of a possible buy-out. Then it pulled back the last two days, causing many to get nervous.
I'm going to stand by my initial report and add the following: It now looks like there may be at least two interested partners/deals in the works.
If my sources are correct, and for the record these are not public relations people or stock pumpers, then this undervalued play could become a big story not only in the short term, but a very solid winner for the long haul as well.
I'm not hyping or sticking my neck out for this, folks.
I'm simply reporting what I am hearing.
How does a move to a bigger exchange sound?
That could also be in play here, but revealing too many details could expose my sources or theirs, so I'll stop here.
Remember, these types of deals don't happen overnight.
Patience is always key.
By the same token, remember that one of the shoes can drop at any moment, so be ready.
For those who think this is some sort of pump and dump scheme on my part, know this: I'm still long and own every single one of my original shares and if it pulls back, I'll pick up even more.
I suggest you do your own due diligence here.
Rumor plays are always risky, but do offer high rewards.
...concerning PM - add me! / will do it over WE
Stocks fall as Obama calls for tougher bank rules
Stocks slide anew as Obama calls for tighter restrictions on some trading by banks
Stephen Bernard and Tim Paradis, AP Business Writers,
On Thursday January 21, 2010, 12:08 pm EST
http://finance.yahoo.com/news/Stocks-fall-as-Obama-calls-apf-1512287612.html;_ylt=ArFaJECrqfyx6R5QIp67fdG7YWsA_ylu=X3oDMTE1NG43dGc2BHBvcwMzBHNlYwN0b3BTdG9yaWVzBHNsawNzdG9ja3NzZWV3b3I-?x=0&sec=topStories&pos=1&asset=&ccode=
NEW YORK (AP) -- Financial shares pulled the stock market lower Thursday as President Barack Obama proposed rules that would limit the types of trading banks can do with their money.
The Dow Jones industrial average tumbled 200 points after dropping 122 points on Wednesday. The index has seen four straight triple-digit swings. Bond prices rose as the stock market became more volatile.
Tightening the rules on how big banks trade their money could hurt profits at those companies.
Broader concerns also dogged investors. Patrick Galley, chief investment officer at RiverNorth Capital in Chicago, said stocks have risen so fast in the past 10 months that expectations about an economic recovery are getting too high.
"The market can be quite fickle just because of the huge run-up that we've had," he said. "A lot of folks have their trigger finger on the sell button if they start to sense that news won't meet expectations."
The market was mixed earlier as good earnings news was tempered by an unexpected jump in initial jobless claims. But banks, which have driven the market over the past year and a half, were the focus by late morning.
The Labor Department said workers filing for unemployment benefits for the first time rose by 36,000 to 482,000 last week. Economists polled by Thomson Reuters were expecting a small drop. The four-week average rose for the first time since August.
The report provided a grim reminder that while the economy might have improved modestly, a robust recovery is unlikely until companies start adding jobs. The unemployment rate remained at 10 percent last month.
Traders said weakness in manufacturing also brought concern that the economy might not be recovering as quickly as hoped. The Philadelphia Federal Reserve said manufacturing in its region fell in January from December. Its index of regional manufacturing conditions fell to 15.2 from a revised 22.5 last month.
In midday trading, the Dow fell 204.58, or 1.9 percent, to 10,398.57. The broader Standard & Poor's 500 index fell 19.31, or 1.7 percent, to 1,118.73. The Nasdaq composite index fell 27.50, or 1.2 percent, to 2,263.75.
Stocks had tumbled on Wednesday after China said it would curb bank lending to slow down its economy. The latest sign of China's supercharged growth came out on Thursday as the country reported 10.7 percent economic expansion in the fourth quarter and 8.7 percent for all of last year. The rapid growth reinforced concerns that China will take more steps to tighten monetary policy and rein in its economy, which could dampen a global economic rebound.
Bond prices jumped as the stock market fell. The yield on the benchmark 10-year Treasury note, which moves opposite its price, fell to 3.62 percent from 3.65 percent late Wednesday.
The dollar rose against other major currencies, while gold fell. A rise in the dollar hurt commodity prices, which become more expensive for foreign buyers when the dollar strengthens.
Crude oil fell 90 cents to $76.84 per barrel on the New York Mercantile Exchange.
The Russell 2000 index of smaller companies fell 10.93, or 1.7 percent, to 628.68.
Four stocks fell for every one that rose on the New York Stock Exchange, where volume came to 586.8 million shares compared with 473.6 million shares traded at the same point Wednesday.
Britain's FTSE 100 fell 1.5 percent, Germany's DAX index lost 1.8 percent, and France's CAC-40 fell 1.7 percent. Earlier, Japan's Nikkei stock average rose 1.2 percent.
Blockbuster "buy," target price raised
11:00a.m. - Wedbush Morgan Securities
http://www.newratings.com/en/main/company_headline.m?id=2014819
NEW YORK, January 21 (newratings.com) - Analysts at Wedbush Morgan reiterate their "buy" rating on Blockbuster (BBI).
The target price has been raised from $1.50 to $1.75.
Janney Capital Markets analyst downgrades Blockbuster to neutral
Thursday, January 21, 2010, 11:23am CST
http://www.bizjournals.com/dallas/stories/2010/01/18/daily36.html?surround=lfn
Rating Action on XL Capital
By: Zacks Equity Research
January 19, 2010
http://www.zacks.com/stock/news/29489/Rating+Action+on+XL+Capital
Rating agency A.M. Best affirmed the rating of XL Capital’s (XL - Analyst Report) subsidiaries with a stable outlook. It includes the affirmation of a financial strength rating (FSR) of “A-“ and an issuer credit rating (ICR) of “a-” for XL Life Ltd., FSR of “A-“ and ICR of “a-” of XL Life Insurance and Annuity Company as well as the ICR of “a-” and the debt ratings for XLLIAC Global Funding.
The rating agency acknowledges XL Life’s adequate capitalization and strong support of the parent. It accounts for life insurance and reinsurance operations of the group.
However, negatives to the ratings include XL Life’s thinning business profile within the group, declining premiums and unfavorable operating results. Moreover, uncertainty and volatility in the markets have led to mark-to-market adjustments and realized losses recently.
XL Capital’s performance has deteriorated in the recent years due to softer policy sales coupled with investment losses. Thus, the company is focusing on those lines of business within its insurance and reinsurance operations that provide the best return on capital over the pricing cycle. The company will be highly selective about new business, emphasizing short-tail lines where applicable in its reinsurance operations, exiting other businesses (e.g., casualty facultative business), not renewing certain insurance programs as well as continuing to reduce long-term agreements (within the insurance operations) in order to reap the benefit of improving pricing. We expect that this selective exposure will result in a reduction in both gross and net premiums written in 2009, and hence further restrict its top-line growth.
Last week, XL Capital announced its intention of shifting its place of incorporation to Ireland from the Cayman Islands.
XL Capital is expected to release fourth quarter 2009 results on Feb. 9, 2010. The Zacks Consensus Estimate for the quarter is a gain of 69 cents per share.
Canadian Superior Closes Private Placement, Appoints Director
Wednesday, January 20, 2010
http://www.rigzone.com/news/article.asp?a_id=86074&rss=true
Canadian Superior successfully closed its previously announced non-brokered private placement January 19, 2010. The Private Placement was over subscribed and the Company raised CDN$59,500,604 issuing 114,424,238 common shares ("Common Shares") at CDN$0.52 per Common Share.
Proceeds from the Private Placement will be used for the Company's exploration and development activities in its domestic and international operations and for general corporate purposes. Jennings Capital Inc. acted as financial advisor to the Company in connection with the Private Placement.
The securities have not been and will not be registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
Appointment of New Director
In conjunction with the closing of the Private Placement, Canadian Superior has appointed James H.T. Riddell to the Company's Board of Directors, effective January 18, 2010. Mr. Riddell is the President and Chief Operating Officer and a Director of Paramount Resources Ltd. Mr. Riddell is also the President, Chief Executive Officer and a Director of Trilogy Energy Ltd., a wholly-owned subsidiary and the administrator of Trilogy Energy Trust. Mr. Riddell graduated from Arizona State University with a Bachelor of Science degree in Geology and from the University of Alberta with a Master of Science degree in Geology.
"I am delighted that Mr. Riddell, a well-respected member of the energy industry, has joined our Board of Directors," said Marvin Chronister, Chairman of Canadian Superior. "His wealth of knowledge and experience in the oil and gas industry will be of great value to the Company as we continue to move forward with the development of our global portfolio of assets."
NexMed Updates on Canadian Aproval Process for Vitaros
Date : 01/19/2010 @ 2:00PM
Source : Business Wire
Stock : NexMed, Inc. (NEXM)
http://ih.advfn.com/p.php?pid=nmona&article=41170706&symbol=NEXM
As U.S. Emerges From Recession, Hartford Mutual Funds Spotlights Why Value Investing May Be Valuable Right Now
Date : 01/19/2010 @ 2:00PM
Source : Business Wire
Stock : The Hartford Financial Services Group, Inc. (HIG)
http://ih.advfn.com/p.php?pid=nmona&article=41170704&symbol=HIG
As U.S. Emerges From Recession, Hartford Mutual Funds Spotlights Why Value Investing May Be Valuable Right Now
While value stocks have performed better than growth stocks sixty percent of the time over the past 20 years (1989-2008) 1, they have stood out particularly after periods of recession. Value companies often become leaner during economic downturns, generate more operating leverage by cutting fixed costs and assets to weather a slower revenue environment, and set the stage for a greater acceleration in earnings as market conditions improve. History shows that value investments have outperformed growth investments for the one-, three-, and five-year time periods following the past four recessions (1/1980-7/1980, 7/1981-11/1982, 7/1990-3/1991, and 3/2001-11/2001)1
INDEX PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. Index Performance does not represent the performance of The Hartford Mutual Funds or any particular investment. Indices measured are Russell 1000 Value and Russell 1000 Growth, which are unmanaged; you cannot invest directly in these indices. Assumes reinvestment of income and no transaction cost. “Why is it that some investment trends always seem to be in style, like value investing?” asks Dr. Bob Froehlich, senior managing director at The Hartford. “It’s the basic premise of investing – you buy low and sell high. What that really means is buying value stocks.” The current opportunity in value investing is the theme of The Hartford Mutual Funds’ latest marketing campaign, which focuses on The Hartford’s value suite of mutual funds:
* The Hartford Balanced Income Fund2, 3: Invests in a mix of approximately 55 percent bonds and 45 percent stocks, with an investment objective to provide income with growth of capital
* The Hartford Equity Income Fund2: Seeks established companies that are currently being overlooked by the market and are trading at a significant discount, and dividend paying companies
* The Hartford Dividend and Growth Fund2: Blends a value-oriented approach with a focus on companies that pay or intend to pay dividends
* The Hartford Value Fund2: Uses a “flexible value” approach to invest across the large-cap value spectrum in companies that have a negatively impacted valuation
* The Hartford Value Opportunities Fund2, 4: Invests primarily in stocks believed to be undervalued and with growth potential across the market-cap spectrum
* The Hartford MidCap Value Fund2, 4: Focuses on midcap companies with below average price/earnings ratio and bottom-up security selection
The Hartford® SMART529®, Offered by the West Virginia College Prepaid Tuition and Savings Board of Directors, also provides investors with the opportunity for value investing as part of the college savings plan’s individual fund options. In that plan, families saving for college may choose among four value options*, which invest in The Hartford mutual fund value investment options5
*The Hartford Equity Income 529 Fund, The Hartford Dividend and Growth 529 Fund, The Hartford Value 529 Fund and The Hartford MidCap Value 529 Fund
A June 2009 Hartford survey of 530 investors over the age of 30 who work with financial advisors found that 81 percent of investors who work with advisors would like to have a dividend-paying stock in their portfolio, yet over half said their advisor has not talked to them about adding this type of option to their portfolio. Seventy-five percent of investors who don’t already hold dividend-paying investments would be open to including them in the future
“We strongly believe in the power of value investing for growth and income,” says Keith Sloane, senior vice president of Hartford Mutual Funds. “We also think there is an opportunity for advisors to talk to their clients about solutions that can provide current income and capital growth.” “Investments seem to be the only thing that retail investors do not want to buy on sale,” says Froehlich. “They shop for cars and clothes at discount prices but when it comes to stocks and investments, ‘on sale’ suddenly makes investors feel uneasy because they think the price is low. One way to heed Warren Buffet’s advice to ‘be fearful when others are greedy and greedy when others are fearful’ is to overweight the value style of investing.” Wellington Management Company, LLP, is an independent and unaffiliated investment sub-adviser to The Hartford’s value-oriented mutual funds. The firm’s experience in value-oriented investing dates back more than eight decades to 1928, when its founder launched America’s first balanced fund
Client brochures and other FINRA-reviewed brochures, articles, letters and emails are available to the public at www.hartfordmutualfunds.com. Financial professionals registered at Hartford Mutual Funds’ broker-only Web site (password protected) can access portfolio manager podcasts and an interactive flashbook which allows advisors to flip though the virtual pages of the brochure while listening to audio commentary from Hartford personal finance experts
The Hartford Value Suite: Performance Summary Class A-Share Average Annual Total Returns Including Maximum 5.5% Sales Charge (as of 12/31/09) Fund Name (Fund Inception Date) 1 Year 5 Years 10 Years Since Inception Gross Operating Expenses6 The Hartford Dividend and Growth Fund (7/22/96) 16.89% 1.56% 3.20% 6.98% 1.09% The Hartford Value Fund (4/30/01) 16.84% 1.59% N/A 1.64% 1.32% The Hartford Equity Income Fund (8/28/03) 11.85% 1.44% N/A 4.48% 1.19% The Hartford Balanced Income Fund (7/31/06) 15.69% N/A N/A 1.60% 1.25% The Hartford MidCap Value Fund (4/30/01) 35.74% 1.08% N/A 4.72% 1.39% The Hartford Value Opportunities Fund (1/2/96) 36.77% -1.31% 2.81% 6.22% 1.42% Performance data quoted represents past performance and is not indicative of future results. The investment return and principal value of an investment will fluctuate so that shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted. For more current performance information to the most recent month ended, please see www.hartfordmutualfunds.com. Performance results are historical and include reinvestment of all distributions at net asset value. Performance information may reflect historical or current expense waivers/reimbursements from an affiliate of the investment advisor, without which performance would have been lower. For more information on waivers/reimbursements, please see prospectus. Performance data quoted does not represent performance of SMART529
About The Hartford Mutual Funds The Hartford Mutual Funds, established in 1996, offers a wide array of both broad-mandate and style-focused equity and fixed-income investment options. The Hartford Mutual Funds draw on the investment strength, experience and expertise of Wellington Management and Hartford Investment Management Co. These two organizations bring their decades of market experience, in-house investment capabilities, rigorous research and time-tested investment process to bear in managing the funds to help The Hartford Mutual Fund investors meet their long-term financial goals. Total retail mutual fund assets under management were $40.1 billion as of September 30, 2009. For more information on The Hartford Mutual Funds, including current holdings, visit www.hartfordmutualfunds.com
About The Hartford Celebrating nearly 200 years, The Hartford (NYSE: HIG) is an insurance-based financial services company that serves households, businesses and employees by helping to protect their assets and income from risks, and by managing wealth and retirement needs. A Fortune 500 company, The Hartford is recognized widely for its service expertise and as one of the world’s most ethical companies. More information on the company and its financial performance is available at www.thehartford.com
HIG-L Some of the statements in this release may be considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. We caution investors that these forward-looking statements are not guarantees of future performance, and actual results may differ materially. Investors should consider the important risks and uncertainties that may cause actual results to differ. These important risks and uncertainties include those discussed in our Quarterly Reports on Form 10-Q, our 2008 Annual Report on Form 10-K and the other filings we make with the Securities and Exchange Commission. We assume no obligation to update this release, which speaks as of the date issued
You should carefully consider investment objectives, risks, and charges and expenses of The Hartford Mutual Funds before investing. This and other information can be found in the Fund's prospectus, which can be obtained from your investment representative or by calling 888-843-7824. Please read it carefully before you invest or send money. 1 INDEX PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. Index Performance does not represent the performance of The Hartford Mutual Funds or any particular investment. The Russell 1000 Value and Growth Indices are unmanaged; you cannot invest directly in these indices. Assumes reinvestment of income and no transaction cost. Recession dates were 1/1980-7/1980, 7/1981-11/1982, 7/1990-3/1991, and 3/2001-11/2001
Indices measured are Russell 1000 Value and Russell 1000 Growth
Russell 1000 Value Index measures the performance of those Russell 1000 Index companies with lower price-to-book ratios and lower forecasted growth values
Russell 1000 Growth Index measures the performance of those Russell 1000 Index companies with higher price-to-book ratios and higher forecasted growth values
Data Source: Morningstar Direct, 10/2009 2 The Fund may invest in foreign securities, which can be riskier than investments in U.S. securities (risks may include currency risk, illiquidity risks, and risks from substantially lower trading volume on foreign markets)
The sub-adviser's investment strategy will influence performance significantly and the Fund could underperform its peers or lose money if that strategy does not perform as expected
3 The Fund is subject to credit risk (the risk that the issuing company may not be able to pay interest and principal when due), interest rate risk (the risk that your investment may go down in value when interest rates rise), and risk of loss (the risk that you could lose money on your investment)
A portion of this Fund’s assets may be below investment grade securities ("high-yield securities" or "junk bonds"), which are rated lower because there is a greater possibility that the issuer may be unable to make interest and principal payments on those securities
The Fund may invest in securities of companies that conduct their principal business activities (or that trade principally on exchanges) in emerging markets (including Asia, Latin America, Eastern Europe, and Africa), which is riskier than investing in securities of more developed countries (including risks of illiquidity and increased price volatility)
4 The Fund invests in securities of small-cap and/or mid-cap companies, which is riskier than stocks of larger companies, because smaller companies generally are young, have limited business history, and frequently rely on narrow product lines and niche markets
5 These are not mutual funds. Fees, charges and expenses are different. Refer to the Offering Statement for additional information
6 Gross operating expenses shown are before management fee waivers or expense caps. Performance information may reflect historical or current expense waivers or reimbursements, without which, performance would have been lower. For more information on fee waivers and/or expense reimbursements, please see the expense table in the prospectus. Wellington Management Company, LLP is an independent and unaffiliated sub-adviser to The Hartford
The Hartford Mutual Funds are underwritten and distributed by Hartford Investment Financial Services, LLC
"The Hartford" is The Hartford Financial Services Group, Inc. and its subsidiaries
SMART529 is offered by the West Virginia College Prepaid Tuition and Savings Program Board of Trustees and is administered by Hartford Life Insurance Company
“The Hartford” is a registered trademark of "Hartford" Fire Insurance Company
“SMART529” is a registered trademark of the West Virginia College Prepaid Tuition and Savings Program Board of Trustees
If you reside in or have taxable income in a state other than West Virginia, you should consider whether your state has a qualified tuition program that offers favorable state income tax or other benefits exclusive to your state’s program that are not available under the SMART529 program. Investments in SMART529 are not guaranteed or insured by the State of West Virginia, the Board of Trustees of the West Virginia College Prepaid Tuition and Savings Program, the West Virginia State Treasurer’s Office, Hartford Life Insurance Company, The Hartford Financial Services Group, Inc., the investment sub-advisors for the Underlying Funds or any depository institution and are subject to investment risks, including the loss of the principal amount invested, and may not be appropriate for all investors. This information is written in connection with the promotion or marketing of the matter(s) addressed in this material. The information cannot be used or relied upon for the purpose of avoiding IRS penalties. These materials are not intended to provide tax, accounting or legal advice. As with all matters of a tax or legal nature, you should consult your own tax or legal counsel for advice
You should carefully consider the investment objectives, risks, charges and expenses of SMART529 and its Underlying Funds before investing. This and other information can be found in the Offering Statement for SMART529 and the prospectuses or other disclosure documents for the Underlying Funds, which can be obtained on SMART529.com or by calling 866-574-3542. Please read them carefully before you invest or send money. SMART529 is distributed by Hartford Securities Distribution Company, Inc. Member SIPC.
Investor Relations Contact
Jeff Stanlis
5025 N Central Avenue, Suite 508
Phoenix, AZ 85012
Phone: 602-476-1821
jeff@haydenir.com
www.haydenir.com
http://www.b2i.us/profiles/investor/fullpage.asp?f=1&BzID=1645&to=cp&Nav=0&LangID=1&s=0&ID=8338
****************
Jeff Stanlis, Partner and Vice President, Communications
Jeff brings a dozen years of corporate communications and marketing experience to Hayden, as well as a dozen years experience as a professional reporter for a variety of major metro daily newspapers and several magazines. Jeff oversees the corporate communications functions for the firm, including messaging and press releases. His expertise includes impactful positioning of client messages, crisis communications, and strategic communications initiatives designed to maximize positive news. Jeff possesses an MBA with a specialty in marketing and an undergraduate degree in journalism.
http://www.haydenir.com/index.php?/static/hayden_ir_team
Success Stories:
American Software, Inc. (Nasdaq: AMSWA)
Arabian American Development Company (Nasdaq: ARSD)
Capital Senior Living, Corp. (NYSE: CSU)
Lucas Energy, Inc. (NYSE Arca: LEI)
Numerex, Inc. (Nasdaq: NMRX)
eResearchTechnology, Inc. (Nasdaq:ERES)
NewCardio, Inc. (OTC BB: NWCI) : http://www.haydenir.com/tinymce/jscripts/tiny_mce/plugins/ajaxfilemanager/uploaded/HIR%20Success%20-%20NWCI.pdf
http://www.haydenir.com/index.php?/static/success_stories
OTC - Pink Sheets Stock Gainers - 1/19/10
http://daytradingstockblog.blogspot.com/2010/01/hot-penny-stocks-11910-january-19-2010.html
...
Stem Cell Innovations, Inc. (SCLL.PK)
...nice to have you on board!
Evergreen Energy Adds to Management Team, Strengthening Presence of GreenCert in Asia Pacific
50 Foxconn Technical Professionals Trained on GreenCert
Tuesday January 19, 2010, 7:00 am
http://finance.yahoo.com/news/Evergreen-Energy-Adds-to-bw-3024673409.html?x=0&.v=1
DENVER--(BUSINESS WIRE)--Evergreen Energy Inc. (NYSE Arca:EEE) hired seasoned software industry executive Mark Ma as General Manager of Asia Pacific for Evergreen. Based in Taipei, Taiwan, Ma will report to Miles Mahoney, president and COO of Evergreen. His responsibilities will be focused on driving sales and marketing and managing client relationships in Asia Pacific, including Foxconn Technology Group. Foxconn has completed the installation of the GreenCert system in Taiwan and is in the process of evaluating the deployment of the system in its various facilities throughout China.
“We are excited to welcome Mark to Evergreen and establish an Asia-based presence for GreenCert and drive our strategic partnership with Foxconn forward,” stated Mahoney. “As we focus our resources on the adoption of our GreenCert solutions into the new multi-regulatory carbon global economy, we identified the need to have a seasoned executive focused on further developing our software and hardware partnerships in Asia Pacific. While at Foxconn, Mark spearheaded the relationships with Evergreen, Enterprise Information Management (EIM) and IBM. We expect his experience with software development and marketing, to drive commercialization of GreenCert in the region.”
“We look forward to working with Mark as he spearheads the execution and delivery of GreenCert with Foxconn in Asia and to build our respective businesses in the region,” stated HL Chen, CIO of Foxconn. “Foxconn has trained 50 technical professionals on GreenCert, and we look forward to working with Evergreen to implement the GreenCert solutions throughout the Asia marketplace, specifically China, which comprises approximately 25% of the world’s coal powered electric output.”
“As carbon management escalates in relevance and importance, the availability of a complete environmental intelligence solution is critical to businesses worldwide,” stated Ma. “I am proud to join a passionate and experienced team. In addition, I am eager to leverage my software and industry knowledge to bring GreenCert to market in Asia Pacific and to further develop our strategic relationship with Foxconn.”
Mark Ma
Mark Ma has 25 years of experience in sales and marketing, business development, alliance/channel management and service delivery. His areas of expertise include ERP, BI, CRM, middleware and software development. Prior to joining Evergreen Energy, Ma was the Director, Business Management Office, GDS Business Group, Foxconn Technology Group. In addition, he served in various roles at major service and software companies including TCS, Atos Origin, SAS, webMethods, SAP and IBM. Ma has a BS in Computer Science from University of California, Berkeley and a MS in Computer Engineering from San Jose State University in the U.S.
Evergreen Energy Inc.
Evergreen Energy Inc. (NYSE Arca: EEE) has developed two proven, proprietary, patented, and transformative green technologies: the GreenCert™ suite of software and services and K-Fuel®. GreenCert, which is owned exclusively by Evergreen, is a scientifically accurate, scalable environment intelligence solution that measures greenhouse gases and generates verifiable emissions credits. K-Fuel technology significantly improves the performance of low-rank coals yielding higher efficiency and lowering emissions. Visit www.evgenergy.com for more information.
Safe Harbor Statement
Statements in this release that relate to future plans or projected results of Evergreen Energy Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended by the Private Securities Litigation Reform Act of 1995 (the "PSLRA"), and Section 21E of the Securities Exchange Act of 1934, as amended by the PSLRA, and all such statements fall under the "safe harbor" provisions of the PSLRA. Our actual results may vary materially from those described in any "forward-looking statement" due to, among other possible reasons, the realization of any one or more of the risk factors described in our annual or quarterly reports, or in any of our other filings with the Securities and Exchange Commission, all of which filings any reader of this release is encouraged to study. In addition, our ability to execute our business plan and develop the C-Lock Technology may be adversely impacted by the inability to sell Buckeye, raise significant additional capital or effectively complete any restructure transaction on a timely basis to fund our business operations. Readers of this release are cautioned not to put undue reliance on forward-looking statements.
Contact:
Lippert / Heilshorn & Associates
Evergreen Investor Contact:
Kirsten Chapman & Becky Herrick, 415-433-3777
bherrick@lhai.com
Evergreen Media Contact:
Adam Handelsman, 212-838-3777
AHandelsman@lhai.com
Cord blood stem cell transplant hopes lifted
Monday, 18 January 2010
http://news.bbc.co.uk/2/hi/health/8462488.stm
A technique which may eventually remove the need for matched bone marrow transplants has been used in humans for the first time.
It is hoped that "master cells" taken from umbilical cords could be used on any patient without rejection.
The latest advance, published in the journal Nature Medicine, greatly multiplies the tiny number of cells from the cord ready for a transplant.
UK charity Leukaemia Research said this could be the "holy grail" for doctors.
Aggressive treatment
The current system of bone marrow transplantation helps patients who have diseases, such as leukaemia, which affect the stem cells in their bone marrow where new blood cells are grown.
Their own bone marrow cells are killed off by aggressive treatment and cells from a matched donor are introduced in their place.
However, a matching donor cannot always be found, despite extensive donor registries held by organisations such as the Anthony Nolan Bone Marrow Trust and, even with a carefully matched donor, there is still a risk that the patient's body will reject the new cells.
Cells extracted from umbilical cords could overcome these problems - they do not have the characteristics which would normally trigger immune rejection, so it is likely that cells from a single baby's cord could be used in any patient, without the need for matching.
However, there is one big disadvantage - there are not enough cells in a single cord to meet the needs of an adult patient.
Scientists have been looking for ways to either combine the cells from more than one baby, or to "expand" the cell numbers in the laboratory.
The second of these options is far from straightforward - simply allowing the stem cells to divide and increase in the laboratory means that many of the resulting extra cells will be simple blood cells, which do not have the ability to produce new cells themselves.
Quick to work
Researchers at the Fred Hutchinson Cancer Research Center in Seattle believe they may have found a way.
They manipulated a "signalling pathway" in the stem cells to trigger an increase in numbers without losing their stem cell status.
After success in laboratory animals, these cells were used in human patients, and the researchers found that they were accepted by the body more quickly and contributed more to the rebuilding of functioning bone marrow than "non-expanded" cord blood transplants.
Dr David Grant, Scientific Director of charity Leukaemia Research said: "The holy grail is to have an 'off the peg' source of unlimited numbers of 'neutral' stem cells which can be given to any patient safe in the knowledge that they will not cause the very difficult 'graft versus host' problems that lead to rejection and often the death of the patient.
"This is a promising development towards this because the concern has been that once stem cells start 'growing' they lose their stem cell properties and progress to ordinary blood cells with a very limited lifespan."
Henny Braund, chief executive of The Anthony Nolan Trust, said the potential for umbilical cord blood was "huge", and that the charity had already imported well over 250 units of umbilical cord blood.
"Sadly in the UK, despite our scientific expertise, umbilical cord blood is still very much an untapped resource and we are only able to collect and store a tiny amount of the cords we need.
"We really need a properly resourced UK cord blood collection programme.
"Further investment is crucial if we are to capitalise on this amazing resource and save more lives."
Cord blood stem cell transplant hopes lifted
Monday, 18 January 2010
http://news.bbc.co.uk/2/hi/health/8462488.stm
A technique which may eventually remove the need for matched bone marrow transplants has been used in humans for the first time.
It is hoped that "master cells" taken from umbilical cords could be used on any patient without rejection.
The latest advance, published in the journal Nature Medicine, greatly multiplies the tiny number of cells from the cord ready for a transplant.
UK charity Leukaemia Research said this could be the "holy grail" for doctors.
Aggressive treatment
The current system of bone marrow transplantation helps patients who have diseases, such as leukaemia, which affect the stem cells in their bone marrow where new blood cells are grown.
Their own bone marrow cells are killed off by aggressive treatment and cells from a matched donor are introduced in their place.
However, a matching donor cannot always be found, despite extensive donor registries held by organisations such as the Anthony Nolan Bone Marrow Trust and, even with a carefully matched donor, there is still a risk that the patient's body will reject the new cells.
Cells extracted from umbilical cords could overcome these problems - they do not have the characteristics which would normally trigger immune rejection, so it is likely that cells from a single baby's cord could be used in any patient, without the need for matching.
However, there is one big disadvantage - there are not enough cells in a single cord to meet the needs of an adult patient.
Scientists have been looking for ways to either combine the cells from more than one baby, or to "expand" the cell numbers in the laboratory.
The second of these options is far from straightforward - simply allowing the stem cells to divide and increase in the laboratory means that many of the resulting extra cells will be simple blood cells, which do not have the ability to produce new cells themselves.
Quick to work
Researchers at the Fred Hutchinson Cancer Research Center in Seattle believe they may have found a way.
They manipulated a "signalling pathway" in the stem cells to trigger an increase in numbers without losing their stem cell status.
After success in laboratory animals, these cells were used in human patients, and the researchers found that they were accepted by the body more quickly and contributed more to the rebuilding of functioning bone marrow than "non-expanded" cord blood transplants.
Dr David Grant, Scientific Director of charity Leukaemia Research said: "The holy grail is to have an 'off the peg' source of unlimited numbers of 'neutral' stem cells which can be given to any patient safe in the knowledge that they will not cause the very difficult 'graft versus host' problems that lead to rejection and often the death of the patient.
"This is a promising development towards this because the concern has been that once stem cells start 'growing' they lose their stem cell properties and progress to ordinary blood cells with a very limited lifespan."
Henny Braund, chief executive of The Anthony Nolan Trust, said the potential for umbilical cord blood was "huge", and that the charity had already imported well over 250 units of umbilical cord blood.
"Sadly in the UK, despite our scientific expertise, umbilical cord blood is still very much an untapped resource and we are only able to collect and store a tiny amount of the cords we need.
"We really need a properly resourced UK cord blood collection programme.
"Further investment is crucial if we are to capitalise on this amazing resource and save more lives."
Stem Cell Transplant Hopes Lifted
Written by Staff and Wire Reports
Monday, 18 January 2010 11:08
http://biomedreports.com/articles/subscriber-only-content/25021-stem-cell-transplant-hopes-lifted.html
CeoCast Newsletter Sunday, January 17 2010
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=45610429
The Future of Biotech: Party Like It's 1999
by: Joseph Krueger January 17, 2010
http://seekingalpha.com/article/182930-the-future-of-biotech-party-like-it-s-1999
...thanks Clay!
NewCardio awarded core patent concerning its CardioBip ECG telemonitoring solution
17. Januar 2010 23:57 - THE MEDICAL NEWS
http://www.news-medical.net/news/20100117/NewCardio-awarded-core-patent-concerning-its-CardioBip-ECG-telemonitoring-solution.aspx
NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic technology provider, announced today that on January 12, 2010, it received notice of allowance for U.S. patent 7,647,093, titled "Apparatus and method for cordless recording and telecommunication transmission of three special ECG leads and their processing," from the U.S. Patent and Trademark Office. This represents the core patent for CardioBip™ and, in conjunction with the two encouraging validation studies announced on January 5, 2010, validates the CardioBip technology, positioning NewCardio as an emerging leader in remote cardiac monitoring.
The CardioBip is a unique, hand-held device that provides a solution for ECG telemonitoring. Patients can carry the CardioBip with them and use it to generate and transmit synthesized, accurate 12-lead ECGs at physician prescribed intervals of time, during ordinary daily activity or when symptoms develop. What makes CardioBip unique is its extreme ease of use, combined with the ability to generate recordings substantially equivalent in quality with standard 12-lead ECGs. The CardioBip works without any cables, cumbersome leads, wires or inconvenient skin electrodes, as the device's electrodes are integrated, offering potential compatibility with popular hand-held PDA platforms.
Branislav Vajdic, Ph.D., chief executive officer of NewCardio, Inc., commented, "This patent strengthens our intellectual property protection creating a significant barrier to entry for a competing device. We believe the CardioBip technology fills an important technological and diagnostic void, enabling not only rhythm diagnosis, but also detection of ischemic ECG changes and precise reconstruction of atrial activity. At present there is no convenient and reliable method for remote monitoring and detection of either ischemic events or derangements of atrial electrical activity, but this patent and the two recently completed validation studies indicate that the CardioBip may potentially fill this need. This patent protects the core technology underlying the CardioBip. The patent comes immediately following the encouraging results from two validation studies, which confirmed CardioBip's ability to record, reconstruct and transmit an accurate, high-resolution 12-lead ECG. NewCardio is committed to advancing the widely accepted 12-lead ECG to deliver innovation to the cardiac sciences. We are gratified by the U.S. Patent and Trademark Office's grant of patent rights and pleased that they approved all 33 claims."
Dorin Panescu, Ph.D., NewCardio's Chief Technical Officer and Vice-President of Research and Development, added, "NewCardio remains committed to an aggressive and comprehensive intellectual property (IP) strategy. The Company's IP portfolio evenly covers innovation and invention for all three of our solutions: QTinno™, CardioBip and Visual3Dx™. The patent issued today stresses the importance NewCardio places on patient-friendly, effective and accurate remote wireless patient monitoring, an important, emerging and under-served segment of health care."
SOURCE NewCardio, Inc.
NewCardio announces two encouraging validation studies related to CardioBip
6. Januar 2010 00:23 - THE MEDICAL NEWS
http://www.news-medical.net/news/20100106/NewCardio-announces-two-encouraging-validation-studies-related-to-CardioBip.aspx
NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic technology provider, announced today two encouraging validation studies related to CardioBip(TM), a hand-held patient-activated device for recording and wireless transmission of reconstructed 12-lead ECGs. The studies confirmed the product's ability to accurately provide wireless remote patient monitoring.
As stated previously in regulatory filings, NewCardio, Inc. sponsored two studies that used CardioBip for wireless remote patient monitoring. CardioBip features fully integrated electrodes and requires no wires to acquire the signal. The acquired signals are transmitted via wireless telephony to a call center where 12-lead ECGs are reconstructed using NewCardio-proprietary algorithms.
Dorin Panescu, Ph.D., NewCardio's Vice President and Chief Technology Officer, commented, "These encouraging study results confirm the CardioBip's ability to record, reconstruct and transmit an accurate, high-resolution 12-lead ECG, thereby enabling not only rhythm diagnosis, but also detection of ischemic ECG changes and precise reconstruction of atrial activity. The Heart Rhythm Society (HRS) Expert Consensus recommends ongoing monitoring for up to two years following catheter or surgical atrial fibrillation (AF) ablation procedures, and our results suggest that the CardioBip may prove particularly useful in detecting AF recurrence after such procedures."
The goal of the studies was to validate the performance of the CardioBip-transmitted 12-lead ECGs when compared to conventional 12-lead ECGs. The first study validated the performance in remote monitoring of acute ischemic events. The second study analyzed the use of CardioBip(TM) for remote monitoring of patients undergoing AF treatment. The studies were conducted by the Clinical Center of Serbia and by the Dedinje Cardiovascular Institute, both located in Belgrade, Serbia.
* In the first study, 47 subjects with angiography-documented coronary artery disease were monitored for ST-segment changes during exercise treadmill testing. Conventional 12-lead ECGs were recorded simultaneous with CardioBip transmitted signals prior to and post exercise. Conventional 12-lead ECGs were treated as the gold standard. Two blinded expert cardiologists determined the number of patients with positive events, the number of leads with positive events and identified the lead that displayed most numerous positive events. Based on all these three criteria, independent statistical analyses showed that the detection rate of exercise-induced acute ischemia by the CardioBip system was equivalent to that obtained by conventional 12-lead ECG analysis.
* In the second study, 18 patients with persistent AF undergoing elective electrical DC cardioversion were studied. One to three wireless 12-lead ECG CardioBip transmissions were performed three to seven days before and up to two weeks after cardioversion. Atrial activity seen in the CardioBip transmitted traces was compared to that determined by conventional 12-lead ECGs in both sinus rhythm and AF. The two blinded expert cardiologists analyzed the number of leads with visible P waves, the P wave polarity and the number of leads with clear AF signal. Independent statistical analyses showed that 12-lead ECGs transmitted with CardioBip and conventional 12-lead ECGs had equivalent performance.
Ihor Gussak, MD, NewCardio's Vice President and Chief Medical Officer, added, "The results of these two clinical validation studies are exceedingly positive and confirm the performance of the NewCardio's CardioBip for remote wireless monitoring of patients with coronary disease and atrial fibrillation. At present there is no convenient and reliable method for remote monitoring and detection of either ischemic events or derangements of atrial electrical activity. The CardioBip is convenient hand-held device that patients can carry with them and use to generate and transmit accurate and complete 12-lead ECGs during ordinary daily activity or when symptoms develop. Such capabilities have the potential to significantly improve clinical outcomes for millions of patients with heart disease."
Dr. Branislav Vajdic, Chief Executive Officer of NewCardio, added, "These successful studies are an extraordinary achievement by NewCardio's technical and medical teams, and represent a scientific landmark for the CardioBip. NewCardio is committed to bringing significant value to each of the more than a quarter billion ECGs performed annually, and this announcement validates the confidence we have in our ability to achieve this important goal. Our platform technology supports a wide-range of applications, and we are increasingly proud, and excited about CardioBip's potential role in remote wireless monitoring of millions of patients with heart disease."
SOURCE NewCardio, Inc.
HAPPY BIRTHDAY!
NWCI Slide Presentation-NewCardio 3D ECG Platform (Visual3Dx)
Posted by: $heff Date: Saturday, January 16, 2010 6:57:12 PM
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=45585302
NewCardio Inc. - Readying For A New Beat?
1/17/2010 2:24 AM ET
http://www.rttnews.com/Content/TopStories.aspx?Node=B1&pageNum=2648_4209_2
(RTTNews) - Visual3Dx is NewCardio's product under development, which has the potential to significantly enhance the value of a standard ECG in assessing potentially fatal diseases and conditions, including acute coronary syndrome. According to the company, Visual3Dx has demonstrated 20% improvement over standard ECG in sensitivity in clinical studies.
CardioBip is yet another product under development. It was awarded a core patent by the U.S. Patent and Trade Office on Thursday. The CardioBip is a hand-held wireless device that provides a solution for ECG telemonitoring. CardioBip's target market is outpatient populations with higher risk for, or with diagnosed, cardiovascular disease.
With promising opportunity in remote patient monitoring, NewCardio sees a lucrative, opportunity for CardioBip, specifically in AF (atrial fibrillation) monitoring. AF, the most common type of arrhythmia, characterized by irregular and often rapid heart rhythm, affects more than two million patients in the U.S. alone. The ageing and baby boomer population also presents a significant market opportunity for the product.
The company plans investing in additional R&D to advance Visual3Dx and CardioBip and the products are expected to be on the market by 2011-2012.
With increasing attention on lowering costs and improving efficiency in healthcare, NewCardio's electrocardiography platform technology that allows faster, more accurate and less expensive assessment of cardiac status, deserves a look and so may the stock. Stay tuned...
without arguments against NWCI, now he reviling FOX Business News...
It's a third-rate biased news org. teetering on the brink of BK.
FOX Business NEWS
http://www.foxbusiness.com/story/markets/industries/health-care/buyout-works-nwci-awarded-key-patent/
Friday, January 15, 2010
"Buyout in the Works" After NWCI is Awarded Key Patent
Jan 15, 2010 (BAYSTREET NEWSWIRE via COMTEX) ----The same biotech news portal that reported RXI Pharmaceuticals' (Nasdaq:RXII) now confirmed partnership talks weeks ahead of time is now reporting that another buyout in the sector may be in the works at this moment.
Their report comes on the heels of Thursday morning's key patent news announcement for small cap innovator, NewCardio (NWCI.OB).
According to BioMedReports, the Silicon Valley based company with a very small share float became the subject of some "credible buyout rumors" on the last day of the recent healthcare conferences in San Francisco.
"Rumors began to fly that the company was suddenly in deep negotiations regarding a buy out," reports M.E. Garza. "After chasing the story, and seeing a key patent announcement hit the news wires on Thursday morning, its my opinion that if the buyout occurs, it will could send shares of NewCardio somewhere between $10 and $14." According to Garza, the company has a hot new technology that is shaping up to be not only the next great diagnostics tool in cardiovascular medicine, but could also turn into "the ultimate medical phone app." There is talk about a hardware/software combo that would allow anyone to hold a smart phone-like device up to their chest in order to interpret/communicate the readings directly to a doctor.
Designers of this technology (who come from a tech background designing chips and microprocessors) have figured out that a great number of doctors simply do not know how to interpret heart monitor signals either correctly or accurately. They feel that EKG technology is "under utilized" as a diagnostics tool and see a multi-billion dollar market for their products.
According to an upbeat presentation at the OneMedForum in San Francisco this week, NewCardio is said to be entering the commercial phase as a cardiac diagnostic and services company.
The company's proprietary software platform technologies reportedly provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's three-dimensional ECG software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development. Developing...
Copyright 2010 BAYSTREET NEWSWIRE
Research Reports - NWCI
Reuters Investment Profile
http://reports.finance.yahoo.com/w0?r=44357742:1
Life Science Analytics
http://reports.finance.yahoo.com/w0?r=42634326:1
CardioBip™ -
http://www.newcardio.com/products-cardio-bip.php
About 70 million Americans have some form of chronic cardiovascular disease. Of those, about 14M have documented coronary artery disease (CAD), with almost one million new cases diagnosed each year. Rapid response to an episode of arrhythmia or ischemia (heart attack) is critical to survival. In a moment of a heart attack, the survival of the patient depends radically on obtaining urgent medical care, essentially based on an ECG recording. Delays in accurate diagnosis are not only costly, but can be fatal. Earlier and more accurate diagnosis allows treatment within the first two hours (“golden hours”) when it is known to be most beneficial.
Research has shown that about 70% of the delay between the onset of the chest pain associated with a heart attack (myocardial infarction) and the intervention is attributed to the patient’s hesitation in seeking medical help. Many factors contribute to this delay, however the key is failure of the patient to recognize the seriousness of the symptoms and the need to immediately go to, an often overcrowded, emergency room. Thus a pocket size ECG machine that would be always with the patient, or high risk person, is needed. Instant wireless transmission of the ECG recording is necessary to dramatically shorten the time between the onset of symptoms and the intervention.
The available pocket-size ECG machines suffer from at least one of two drawbacks. They are either easy to use, but offer only a couple of channels, which reduces them to arrhythmia monitors, or they have leads (wires) that typically require a trained person (nurse) to attach them to the patient’s body.
CardioBip™ Hand Held Device
CardioBip™ is a unique, hand held device that offers the solution to the problem of urgent ECG telemonitoring, capable of providing truly comprehensive and accurate ECG data that is being transmitted wirelessly. CardioBip™ is unique due to its extreme ease of use, as it employs only three integrated electrodes, combined with the ability to generate a standard 12 lead ECG recording. The absence of any cables and integrated nature of its electrodes offers the potential for an integration with popular hand held PDA platforms.
Features
* CardioBip™ is a cordless pocket device not requiring patient connection by leadwires.
* Recordings are simply made by holding the instrument against the patient’s chest, similar to single lead devices.
* The CardioBip™ device has 3 integrated leads that make contact with the patient’s chest.
* The unique data collected by CardioBip™ provides sufficient information to allow accurate, immediate reconstruction of a complete 12-lead ECG from a calibrated, patient-specific transformation matrix.
* The CardioBip-transmitted data may also be analyzed with the Visual3Dx array of 3-D analytical tools.
These features enable more accurate and timely diagnoses of acute cardiac events, and facilitate immediate intervention in life-threatening situations – even when the patient is far removed from a medical care center.
CardioBip™ Hand Held Device
Visual3Dx™ -
http://www.newcardio.com/products-visual-ecg.php
Although diagnostically valuable, the standard 12-lead ECG has significant limitations. The ECG is a 2-dimensional representation of cardiac electrical activity, an inherently 3-dimensional event. As a consequence, significant amounts of important information are not used because the human mind is not capable of synthesizing all of this complex information. In addition, errors in interpreting the standard 12-lead ECG are common and can lead to serious clinical mismanagement. Errors of “major proportions” have been identified in 4% to 32% of ECG interpretations. The fear of wrong diagnoses and the associated legal liability results in many unnecessary admissions to hospitals of patients with chest pain. Many independent estimates put the cost of these unnecessary admissions in the US at well over $5 billion. New analysis approaches are urgently needed to reduce interpretative error and to improve diagnostic accuracy.
Visual3Dx™ Software
Visual3Dx™ is a set of algorithms and tools that provide a comprehensive method to describe cardiac electrical activity in time and space. Visual3Dx™ extracts additional information from standard 12-lead ECG signals and uses it to generate a 3D representation of cardiac electrical activity as a function of time. To further enhance understanding and ease of use, the program superimposes the diagnostically relevant electrical information on an intuitive, revolving 3-D anatomic model of the heart.
A key aspect of Visual3Dx™ is its suite of algorithms to correct the problem of variation in electrical attenuation across the chest wall. This leads to regional inconsistency and poor diagnostic sensitivity in remote regions of the heart. To correct this problem, Visual3Dx™ includes algorithms to normalize electrical attenuation, which results in a "virtual sphere" of normalized electrical activity, and ensures accurate and balanced representation of all heart regions.
We believe Visual3Dx’s features enable it to detect serious cardiac diseases with far greater sensitivity and specificity than is possible with a standard ECG. Importantly, however, Visual3Dx™ requires no change in standard 12-lead ECG practice. The ECG is obtained exactly as it is now, with the electrodes placed in the same locations without need for additional electrodes. Moreover, Visual3Dx™ displays the standard 12-lead ECG along with its novel 3-D analytical presentations. This allows the physician to make correlations between displays and provides reassurance that no information has been lost.
A typical Visual3Dx™ output that is easy to read and thus requires less training to interpret, when compared with the standard 12-lead display.
QTinno™ -
http://www.newcardio.com/products-qtinno.php
The FDA requires that all new drugs be tested for potential cardiac toxicity early in development. Screening for the risk of drug-induced adverse, often lethal, cardiovascular events – such as those identified with Vioxx®, Seldane®, and Avandia® is of utmost importance for drug developers, and the public health in general. New drugs are often tested on more than 1,000 subjects, with ECGs collected at multiple time points. Current semi-automated methods for arrhythmia induced cardiac toxicity are costly and time-consuming. Using NewCardio’s 3-D approach, drug Sponsors and Contract Research Organizations (CROs) can automate this process, significantly reducing the cost and variability compared with non-automated methods, and reducing the time required to test new drugs in development.
QTinno™ Tools
QTinno™ is a software suite that provides accurate, fully automated and comprehensive analysis of QT intervals, and other ECG markers for cardiac safety assessment in drug development.
Key features
* novel, fully automated assessment tool
* sophisticated, proprietary curve-fitting algorithms to identify key cardiac events
* fast, accurate and precise QT data from a broad range of difficult ECGs, and
* QTinno Client™ provides user friendly software platform for fast, informative human overview of QTinno™ results, if desired.
The QTinno™ algorithm first processes the input signal into a 3D representation of cardiac electrical activity over time. It then generates a "virtual sphere" of normalized cardiac electrical activity that includes balanced and complete information from all parts of the heart. This improves the signal-to-noise ratio and shows difficult-to-detect events with substantially greater clarity than the standard 12-lead display. In addition, QTinno™ incorporates novel curve fitting algorithms that ensure a high degree of accuracy. These advantages enable reliable, fully automated identification of key cardiac events - a problem previously unsolved.
QT Client™
QT Client™, which provides a user friendly software platform for fast, informative overview of QTinno™ results.
The QT Client™ user interface has been carefully designed to meet user needs, both in display and data analysis. Among other things, QT Client™ provides the user with an output that identifies the exact time of all key cardiac events used in analysis – such as Q onset, end of the T wave, heart rate, raw and rate-corrected QT interval, and statistical analysis.
In summary, we believe that for the first time, the definitive solution for automated, thorough or routine QT studies is being offered. QTinno™ by NewCardio will be differentiated in the market by the following features.
* QTinno™ offers productivity and precision of automation and highly accurate results – even on more “difficult” ECGs
* Robust QTinno™ technology potentially adaptable to rapidly emerging problem of drug-induced propensity to increased rates of adverse cardiac events
* NewCardio’s solution provides more accurate, more efficient, lower cost, and lower risk assessments of cardiac safety.
QTinno™ performance was validated using thousands of ECGs. Two drugs under development were evaluated for cardiac toxicity using QT interval change as the marker. Both studies returned remarkable agreement with the gold standard that was generated by extraordinary careful manual or semi-automated reading by multiple highly qualified cardiologists. Peer reviewed publications are in preparation.
A QT Client™ user screen – one of several displays possible for user inspection of QT results.
INO-presentation at OneMedForum
http://www.ustream.tv/recorded/3955877
...tommorow is my 1st-ihub-anniversary !
( Alias Born On: Sunday, January 18, 2009 )
http://investorshub.advfn.com/boards/profile.asp?user=141030
http://investorshub.advfn.com/boards/profile.asp?user=185769
Posted by: EJo Date: Sunday, January 17, 2010 7:26:10 AM
In reply to: None Post # of 22579
Do not buy ZVTK